Literature DB >> 26106033

sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia.

Leandro De Oliveira1, José C Peraçoli2, Maria T Peraçoli2, Henri Korkes3, Giafranco Zampieri4, Antonio F Moron5, Nelson Sass3.   

Abstract

Soluble fms-like tyrosine kinase 1 (sFlt-1) is an anti-angiogenic factor released in higher amounts by preeclamptic placentas and it has been implicated in the endothelial dysfunction observed in the disease. In this study we evaluated if circulating sFlt-1/PlGF ratio is useful to predict adverse outcomes in women with early-onset preeclampsia. This is a cohort study of 88 preeclamptic women with singleton pregnancies at ⩽35weeks of gestation. According to definitions used, adverse outcomes occurred in 46.5% (N=43) of the patients. The median sFlt1/PlGF ratio (25th-75th centile) for all patients evaluated was of 42.26 (13.1-226.1). The median sFlt-1/PlGF ratio among women who had any adverse outcome (N=43) versus no adverse outcomes (N=45) was of 227.6 (80.3-346.1) versus 14.4 (3.35-30.0), (P<0.0001). According to our analyses a sFlt-1/PlGF ratio cut-point of ⩾85 gave a sensitivity of 74.0% and specificity of 97.0%. The positive predictive value and the negative predictive value were 96.0% and 80.0%, respectively. The median sFlt-1/PlGF ratio (25th-75th centile) for patients who delivered within <7days was 260.0 (127.7-404.7) as compared to 14.4 (3.35-34.97) for those patients who delivered within two weeks or more (P<0.0001). Our results suggest that sFlt-1/PlGF ratio is a promising marker for adverse outcomes in women with early-onset preeclampsia.
Copyright © 2013 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; PlGF; Preeclampsia; sFlt-1

Year:  2013        PMID: 26106033     DOI: 10.1016/j.preghy.2013.02.003

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  5 in total

1.  Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).

Authors:  Christopher A Mecoli; Jamie Perin; Jennifer E Van Eyk; Jie Zhu; Qin Fu; Andrew G Allmon; Youlan Rao; Scott Zeger; Fredrick M Wigley; Laura K Hummers; Ami A Shah
Journal:  Clin Rheumatol       Date:  2019-12-19       Impact factor: 2.980

Review 2.  Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review.

Authors:  U Vivian Ukah; Jennifer A Hutcheon; Beth Payne; Matthew D Haslam; Manu Vatish; J Mark Ansermino; Helen Brown; Laura A Magee; Peter von Dadelszen
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

Review 3.  Could Vitamin D Be Effective in Prevention of Preeclampsia?

Authors:  Elżbieta Poniedziałek-Czajkowska; Radzisław Mierzyński
Journal:  Nutrients       Date:  2021-10-28       Impact factor: 5.717

4.  Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia.

Authors:  Ingrid C Weel; Rebecca N Baergen; Mariana Romão-Veiga; Vera T Borges; Vanessa R Ribeiro; Steven S Witkin; Camila Bannwart-Castro; Jose C Peraçoli; Leandro De Oliveira; Maria T Peraçoli
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

5.  Placental growth factor for the prognosis of women with preeclampsia (fullPIERS model extension): context matters.

Authors:  U Vivian Ukah; Beth A Payne; Jennifer A Hutcheon; Lucy C Chappell; Paul T Seed; Frances Inez Conti-Ramsden; J Mark Ansermino; Laura A Magee; Peter von Dadelszen
Journal:  BMC Pregnancy Childbirth       Date:  2020-11-05       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.